Nothing Special   »   [go: up one dir, main page]

CR20170221A - Antagonista de A2A de dosis baja para el tratamiento de TDAH y la enfermedad de Parkinson - Google Patents

Antagonista de A2A de dosis baja para el tratamiento de TDAH y la enfermedad de Parkinson

Info

Publication number
CR20170221A
CR20170221A CR20170221A CR20170221A CR20170221A CR 20170221 A CR20170221 A CR 20170221A CR 20170221 A CR20170221 A CR 20170221A CR 20170221 A CR20170221 A CR 20170221A CR 20170221 A CR20170221 A CR 20170221A
Authority
CR
Costa Rica
Prior art keywords
parkinson
antagonist
disease
treatment
adhd
Prior art date
Application number
CR20170221A
Other languages
English (en)
Inventor
Johan Areberg
Lone Frydelund Larsen
Nathalie Breysse
Gamini Chandrasena
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of CR20170221A publication Critical patent/CR20170221A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La presente invención se refiere a dosis específicas de un antagonista de A2A para utilizarlo como un medicamento y, en particular, que sean útiles para el tratamiento de la enfermedad de Parkinson y del trastorno por déficit de atención con hiperactividad.
CR20170221A 2014-12-03 2015-12-01 Antagonista de A2A de dosis baja para el tratamiento de TDAH y la enfermedad de Parkinson CR20170221A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201400704 2014-12-03
PCT/EP2015/078181 WO2016087429A1 (en) 2014-12-03 2015-12-01 Low dosage a2a antagonist for the treatment of adhd and parkinsons

Publications (1)

Publication Number Publication Date
CR20170221A true CR20170221A (es) 2017-10-05

Family

ID=58731664

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20170221A CR20170221A (es) 2014-12-03 2015-12-01 Antagonista de A2A de dosis baja para el tratamiento de TDAH y la enfermedad de Parkinson

Country Status (25)

Country Link
US (2) US20160158211A1 (es)
EP (1) EP3226863A1 (es)
JP (1) JP2017536400A (es)
KR (1) KR20170090430A (es)
CN (1) CN106999480A (es)
AU (1) AU2015357197A1 (es)
BR (1) BR112017011777A2 (es)
CA (1) CA2966582A1 (es)
CL (1) CL2017001407A1 (es)
CO (1) CO2017004785A2 (es)
CR (1) CR20170221A (es)
DO (1) DOP2017000121A (es)
EA (1) EA201790973A1 (es)
EC (1) ECSP17030050A (es)
IL (1) IL252355A0 (es)
MA (1) MA41090A (es)
MX (1) MX2017007027A (es)
NI (1) NI201700066A (es)
PE (1) PE20170926A1 (es)
PH (1) PH12017500923A1 (es)
SG (1) SG11201704370XA (es)
SV (1) SV2017005441A (es)
TN (1) TN2017000174A1 (es)
TW (1) TW201632186A (es)
WO (1) WO2016087429A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3105721A1 (en) 2018-07-05 2020-01-09 Incyte Corporation Fused pyrazine derivatives as a2a / a2b inhibitors
KR20210114963A (ko) 2019-01-11 2021-09-24 오메로스 코포레이션 암을 치료하기 위한 방법 및 조성물
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
CN114917350B (zh) * 2022-06-21 2023-06-13 重庆医科大学附属第二医院 Cftr增强剂在注意缺陷与多动障碍中的应用及产品

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2629414T3 (es) * 2003-12-26 2017-08-09 Kyowa Hakko Kirin Co., Ltd. Derivados de tiazol
WO2010010908A1 (ja) * 2008-07-23 2010-01-28 協和発酵キリン株式会社 片頭痛治療剤
TWI548411B (zh) * 2009-04-28 2016-09-11 Kyowa Hakko Kirin Co Ltd Exercise disorder treatment
UA110097C2 (uk) * 2009-09-02 2015-11-25 Терапевтичний агент для лікування розладів настрою
UA113383C2 (xx) * 2009-09-02 2017-01-25 Терапевтичний агент для лікування тривожних розладів

Also Published As

Publication number Publication date
PH12017500923A1 (en) 2017-11-20
NI201700066A (es) 2018-01-04
EP3226863A1 (en) 2017-10-11
EA201790973A1 (ru) 2017-10-31
DOP2017000121A (es) 2017-07-15
JP2017536400A (ja) 2017-12-07
AU2015357197A1 (en) 2017-05-25
CO2017004785A2 (es) 2017-08-31
SG11201704370XA (en) 2017-06-29
MX2017007027A (es) 2017-08-24
CA2966582A1 (en) 2016-06-09
TW201632186A (zh) 2016-09-16
US20160158211A1 (en) 2016-06-09
ECSP17030050A (es) 2017-08-31
PE20170926A1 (es) 2017-07-13
WO2016087429A1 (en) 2016-06-09
CN106999480A (zh) 2017-08-01
IL252355A0 (en) 2017-07-31
SV2017005441A (es) 2017-08-25
CL2017001407A1 (es) 2018-01-05
US20180125835A1 (en) 2018-05-10
MA41090A (fr) 2017-10-10
KR20170090430A (ko) 2017-08-07
BR112017011777A2 (pt) 2018-02-20
TN2017000174A1 (en) 2018-10-19

Similar Documents

Publication Publication Date Title
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
ECSP17018120A (es) Triazolopirazinonas como inhibidores de pde1
DOP2015000241A (es) Compuestos de biaril-amida como inhibidores de cinasa
BR112017008659A2 (pt) ?métodos e compostos de agonista de gip?
CR20130377A (es) Métodos y productos de fármaco para tratar enfermedad de alzheimer
CL2015003343A1 (es) Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico.
DOP2017000254A (es) Imidazopirazinonas como inhibidores de pde1
SV2017005412A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
DOP2017000121A (es) Antagonista de a2a de dosis baja para el tratamiento de tdah y la enfermedad de parkinson
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
DOP2016000170A (es) Compuestos derivados de hidroxiformamida y usos del mismo
BR112017008481A2 (pt) composto antimicótico
BR112016015997A2 (pt) ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas?
UY35438A (es) Procedimiento para preparar inhibidores de la glucosilceramida sintasa.
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
CL2016000019A1 (es) Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión.
CR20170090A (es) Derivados de terahidroquinolina como inhibidores del bromodominio
BR112019006504A2 (pt) regime de dosagem de avelumabe para o tratamento de câncer
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
ECSP16082599A (es) Quinazolin-thf-aminas halogenadas como inhibidores de pde1
BR112017016333A2 (pt) compostos anticâncer
ECSP16071574A (es) Hexahidrofuropirroles como inhibidores de pde1
CL2015001481A1 (es) Uso de extracto bacopa monnieri
DOP2015000290A (es) Benzoxazoles sustituidos
NZ725354A (en) Transdermal formulations of pergolide and uses thereof